Rituxan®
Understanding Rituxan® (rituximab)
Rituxan® is a monoclonal antibody used to treat autoimmune diseases and certain types of cancer by targeting CD20, a protein found on B-cells. By binding to CD20, Rituxan® marks B-cells for destruction by the immune system, helping to reduce inflammation and abnormal immune responses in autoimmune diseases while also depleting cancerous B-cells in blood cancers.
How Rituxan® Works:
- Targets and eliminates CD20-positive B-cells, which contribute to autoimmune diseases and blood cancers.
- Reduces inflammation and immune system overactivity in autoimmune conditions.
- Helps slow disease progression and improve symptoms in cancer and immune-mediated disorders.
FDA Approval:
- Rituxan®: Approved in 1997
For more information, please visit the Rituxan® patient website and speak with your healthcare provider to determine if Rituxan® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: CancerChronic Kidney DiseaseChronic Spontaneous Urticaria (CSU)Crohn’s Disease (IBD)Cytokine Release Syndrome (CRS)DermatomyositisGiant Cell Arteritis (GCA)Granulomatosis With Polyangiitis (GPA)Immune Thrombocytopenic Purpura (ITP)Juvenile Idiopathic Arthritis (JIA)LupusLupus NephritisMicroscopic Polyangiitis (MPA)Nephrotic SyndromeNeuromyelitis Optica Spectrum Disorder (NMOSD)Pemphigus Vulgaris (PV)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE) |
MANUFACTURER: Genentech (Roche) & Biogen |
CLASS: Anti-CD20 Monoclonal Antibody
B-Cell Depleting Therapy |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Initial dose: Two infusions, two weeks apart – Maintenance: Every six months or as needed |
Length of infusion: Varies, depending on the condition being treated. |
FOR MORE INFORMATION: |
Related drugs
